Watch for enrollment completion of the BCG-Unresponsive NMIBC cohort by year-end and interim THRIVE-3 Phase 2b results, both catalysts for TARA-002 and IV Choline Chloride programs. The in-sourcing of manufacturing adds operational control but increases near-term cash burn.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $2.30entry
- T+1 · 8d ago +9.13%α +6.76% · $2.51
- T+5 · 4d ago +10.00%α +7.41% · $2.53
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Protara Therapeutics reported a Q3 2026 net loss of $21.7M ($0.35 per share), wider than the $13.3M loss a year ago, as R&D spending rose to $16.8M. The company provided clinical updates: expects to complete enrollment of the BCG-Unresponsive NMIBC cohort by year-end 2026 and the STARBORN-1 LM trial in early Q1 2027, with a rolling BLA for TARA-002 in LMs targeted for 2H 2027. Cash of $143M is expected to fund operations into 2028.
Key Financial Metrics
Key Facts
- Q3 2026 net loss $21.7M ($0.35/sh) vs $13.3M ($0.31/sh) in Q3 2025
- R&D expenses $16.8M, up from $9.6M year-over-year
- Cash, equivalents and marketable debt securities $143.1M as of Sep 30, 2026
- Expects to complete enrollment of BCG-Unresponsive NMIBC cohort by year-end 2026
- STARBORN-1 LM trial enrollment now expected to complete early Q1 2027
- Rolling BLA submission for TARA-002 in LMs expected in 2H 2027
- Acquired TARA-002 manufacturing assets from Novex Innovations for $8.75M
- THRIVE-3 Phase 2b enrollment completed; interim results expected by year-end 2026
Financial Impact
Net loss widened by $8.4M vs prior year; cash burn increased; $143M cash runway into 2028
Risk Factors
- Clinical trial enrollment delays (STARBORN-1 pushed to early Q1 2027)
- Rising R&D spend without near-term revenue
- Regulatory risk for BLA submission and FDA approval of TARA-002
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3397475 |
Track record
13 reports on TARA
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.50% at T+60 after the May 26, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Neutral 4/10 Viewing Entry $2.30 Now $2.38 +3.48% settles Feb 4
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
- Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
- May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
- May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
- May 13, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers